| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $1,442,043 ) |
| | 2026 | 2026 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 5 | NIH | 3/13/2026 | $27,612 |
| | 2026 | 2026 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 5 | NIH | 1/30/2026 | $874,399 |
| | 2026 | 2026 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R61AI187095 | Designing a Robust Platform for the In vitro Propagation of Babesia Microti in Human RBCs | 000 | 2 | NIH | 11/26/2025 | $427,000 |
| | 2026 | 2026 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | K99AI182422 | Structural and Functional Alteration of host RBCs by Babesia | 000 | 2 | NIH | 12/2/2025 | $134,730 |
| | 2026 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21HL175096 | Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients | 000 | 2 | NIH | 2/27/2026 | $0 |
| | 2026 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 6 | NIH | 2/6/2026 | $0 |
| | 2026 | 2025 | NEW YORK BLOOD CENTER, INC | 601 MIDLAND AVE | RYE | NY | 10580-4000 | WESTCHESTER | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 5 | NIH | 4/2/2026 | $0 |
| | 2026 | 2024 | NEW YORK BLOOD CENTER, INC | 601 MIDLAND AVE | RYE | NY | 10580-4000 | WESTCHESTER | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 001 | 5 | NIH | 4/7/2026 | $0 |
| | 2026 | 2023 | NEW YORK BLOOD CENTER, INC | 601 MIDLAND AVE | RYE | NY | 10580-4000 | WESTCHESTER | USA | R21AI171525 | Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury | 000 | 2 | NIH | 1/8/2026 | -$888 |
| | 2026 | 2023 | NEW YORK BLOOD CENTER, INC | 601 MIDLAND AVE | RYE | NY | 10580-4000 | WESTCHESTER | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 000 | 3 | NIH | 12/16/2025 | -$4,656 |
| | 2026 | 2023 | NEW YORK BLOOD CENTER, INC | 601 MIDLAND AVE | RYE | NY | 10580-4000 | WESTCHESTER | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 000 | 3 | NIH | 12/16/2025 | -$16,153 |
|
| Issue Date FY: 2025 ( Subtotal = $8,380,383 ) |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21HL175096 | Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients | 000 | 2 | NIH | 9/8/2025 | $128,100 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH140665 | Influence of Social Networks on HIV Testing and PrEP Care among Young Latin American Gay, Bisexual, and Other Men Who Have Sex with Men | 000 | 1 | NIH | 9/22/2025 | $485,131 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI193881 | Development of a radiation countermeasure with sex-dependent radiation response. | 000 | 1 | NIH | 7/15/2025 | $170,800 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL181370 | Erythroblastic island macrophages in normal erythropoiesis and disordered erythropoiesis in polycythemia vera | 000 | 1 | NIH | 7/23/2025 | $801,628 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH136915 | Impact of geographic mobility on pre-exposure prophylaxis and HIV care outcomes | 002 | 2 | NIH | 9/8/2025 | $177,638 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 000 | 3 | NIH | 8/19/2025 | $815,643 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 5 | NIH | 5/20/2025 | $719,415 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 4 | NIH | 7/21/2025 | $92,043 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 4 | NIH | 11/15/2024 | $828,377 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 6 | NIH | 7/3/2025 | $3,043,095 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI183544 | Effects of Exogenous Hormone Treatment on Vaccine Responses | 000 | 1 | NIH | 12/16/2024 | $267,121 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | K99AI182422 | Structural and Functional Alteration of host RBCs by Babesia | 000 | 1 | NIH | 12/13/2024 | $134,730 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R61AI187095 | Designing a Robust Platform for the In vitro Propagation of Babesia Microti in Human RBCs | 000 | 1 | NIH | 12/13/2024 | $427,000 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI183544 | Effects of Exogenous Hormone Treatment on Vaccine Responses | 002 | 1 | NIH | 8/29/2025 | $0 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AI183544 | Effects of Exogenous Hormone Treatment on Vaccine Responses | 001 | 1 | NIH | 3/10/2025 | $0 |
| | 2025 | 2025 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 5 | NIH | 5/8/2025 | $495,320 |
| | 2025 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH136915 | Impact of geographic mobility on pre-exposure prophylaxis and HIV care outcomes | 000 | 1 | NIH | 3/21/2025 | $0 |
| | 2025 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH136915 | Impact of geographic mobility on pre-exposure prophylaxis and HIV care outcomes | 001 | 1 | NIH | 8/14/2025 | $0 |
| | 2025 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 000 | 9 | NIH | 7/3/2025 | $0 |
| | 2025 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 001 | 11 | NIH | 7/22/2025 | -$361 |
| | 2025 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 4/10/2025 | $0 |
| | 2025 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21AR079766 | Autophagic regulation of inflammasome-mediated hyperactive state in living macrophages | 000 | 3 | NIH | 11/27/2024 | -$1,602 |
| | 2025 | 2022 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01MH118960 | Neighborhoods, Networks, and the HIV Care Continuum among HIV-infected MSM in NYC | 000 | 4 | NIH | 7/7/2025 | -$4 |
| | 2025 | 2021 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01DK032094 | Red Cell Membrane Studies | 000 | 33 | NIH | 1/3/2025 | -$203,692 |
|
| Issue Date FY: 2024 ( Subtotal = $7,330,051 ) (Continued on the next page) |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC. | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 000 | 3 | NIH | 12/6/2023 | $828,377 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL165202 | Transfusion-driven hyperhemolysis in sickle cell disease | 001 | 2 | NIH | 6/14/2024 | $799,330 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R35HL161239 | Immune Pathophysiology of Sickle Cell Disease | 001 | 3 | NIH | 6/12/2024 | $73,634 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL124015 | Latexin function in the maintenance and regeneration of the hematopoietic system | 002 | 9 | NIH | 7/3/2024 | $427,000 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | P01HL149626 | Complications of Hemolysis and Transfusion Therapy | 000 | 5 | NIH | 7/15/2024 | $3,041,589 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21MH136915 | Impact of geographic mobility on pre-exposure prophylaxis and HIV care outcomes | 000 | 1 | NIH | 8/29/2024 | $308,371 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 001 | 4 | NIH | 7/16/2024 | $134,320 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | U01AI160421 | Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | 000 | 4 | NIH | 5/13/2024 | $719,415 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R21HL175096 | Evaluating accessory cells to improve homing and engraftment efficiency of CD34+ cells from sickle cell disease patients | 000 | 1 | NIH | 8/21/2024 | $128,100 |
| | 2024 | 2024 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01HL155574 | Hormetic ER Stress Regulation of Hematopoietic Stem Cell Function | 000 | 4 | NIH | 5/13/2024 | $485,415 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R56AI104416 | Design of inhibitors targeted to the CD4 binding site on HIV - 1gp120 | 000 | 11 | NIH | 5/16/2024 | $0 |
| | 2024 | 2023 | NEW YORK BLOOD CENTER, INC | 310 E 67TH ST | NEW YORK | NY | 10065-6275 | NEW YORK | USA | R01DK130478 | Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells. | 001 | 3 | NIH | 11/6/2023 | $18,566 |
|
